Summary of ACADIA Pharmaceuticals Conference Call Company Overview - **Company**: ACADIA Pharmaceuticals (NasdaqGS:ACAD) - **Focus**: Development of treatments for central nervous system disorders, particularly Alzheimer's disease psychosis and Lewy body dementia psychosis Key Points Alzheimer's Disease Psychosis Program - **Next Generation Molecule**: Remlifanserin (formerly ACP-204), a 5-HT2A inverse agonist, aims to improve upon pimavanserin (NUPLAZID), the first approved treatment for Parkinson's disease psychosis [4][5] - **Goals**: - Reduce QT prolongation risk - Allow for greater dose ranging - Achieve faster time to steady state [4][5] - **Current Status**: Remlifanserin is in phase 2 trials for both Alzheimer's disease psychosis and Lewy body dementia psychosis [5] Comparison with Pimavanserin - **Pimavanserin's Efficacy**: Mixed results in indications like schizophrenia and major depressive disorder, but showed potential in Alzheimer's [9][10] - **Expectations for Remlifanserin**: Higher probability of success due to improved study design and molecule characteristics, including the ability to achieve higher exposure levels [10][11] Trial Design Improvements - **Study Design**: The new trial is community-based rather than limited to nursing homes, ensuring a more representative patient population [18] - **Endpoints**: Utilizing SAPS-H+D for better sensitivity to change compared to the previous NPI-NH scale [19] - **Powering**: The phase 2 study is powered for a moderate effect size of 0.4 with 80% power [24] Regulatory Considerations - **FDA Interaction**: The company is gathering data rigorously to address safety concerns, particularly regarding the black box warning associated with pimavanserin [26][28] - **Potential for Phase 2 as Pivotal Trial**: The phase 2 study is designed to be rigorous enough to potentially serve as a pivotal trial, depending on the outcomes [32][34] Lewy Body Dementia - **Biomarker Testing**: The study will include alpha-synuclein biomarkers to differentiate between patient subpopulations [64][65] - **Comparative Probability of Success**: There is a belief that Lewy body dementia may have a higher probability of success compared to Alzheimer's disease psychosis, although both have their merits [58][59] Other Pipeline Assets - **ACP-211**: A selectively deuterated R-ketamine for major depressive disorder (MDD) is in development, aiming for ketamine-like efficacy without sedation and dissociation [73][74] - **Phase 2 Study Goals**: To assess efficacy while ruling out unacceptable levels of sedation and dissociation [74] Upcoming Data Readouts - **Timeline**: Data readouts for the Alzheimer's disease psychosis program (remlifanserin) are expected between August and October [81][82] Additional Considerations - **Patient Compliance**: The ease of administration and safety profile are critical for patient adherence to the treatment [49][50] - **Long-term Safety**: While the phase 2 study will not definitively answer long-term cognitive impact, it will provide initial insights [56][57] This summary encapsulates the key discussions and insights from the ACADIA Pharmaceuticals conference call, focusing on their ongoing research and development efforts in treating Alzheimer's disease psychosis and Lewy body dementia.

Summary of ACADIA Pharmaceuticals FY Conference Call Company Overview - **Company**: ACADIA Pharmaceuticals (NasdaqGS:ACAD) - **Date of Conference**: March 02, 2026 Key Financial Projections - **Revenue Guidance for 2028**: Projected net sales of **$1.7 billion** - **NUPLAZID**: $1 billion - **Daybue**: $700 million - **Growth Rate for NUPLAZID**: Expected **12% growth** in 2026 and similar in 2027 - **Growth Rate for Daybue**: Expected **20% growth** in the current year [7][13][15] Product Performance and Strategies NUPLAZID - **Fourth Quarter Growth**: Reported **18% growth** in MBRXs (monthly active patients) [13] - **Marketing Strategy**: Focused on direct consumer campaigns and an expanded field force, increasing targets from **7,000 to 11,000 physicians** [13][21] - **Field Force Expansion**: Increased by **30%**, expected to impact growth in the latter half of the year [13][14] Daybue - **Current Market Penetration**: Approximately **27%** in the community setting, expected to rise to the early **30s** by year-end [15][198] - **New Product Launch**: DAYBUE STIX, a new formulation aimed at improving patient adherence and flexibility [15][16] - **Expected Incremental Patients**: Approximately **400 additional patients** expected to be unlocked through the new formulation by 2028 [212] Pipeline Developments Remlifanserin (204) - **Phase 2 Data Timeline**: Expected between **August and October** [37] - **Study Design**: Focused on Alzheimer's disease psychosis with a primary endpoint of SAPS H&D at week 6 [51][52] - **Patient Population**: Enrolling around **300 patients** [53] Clinical Rationale - **Biological Rationale**: Targeting serotonin signaling disruption in Lewy body dementia and Alzheimer's disease psychosis [182] - **Clinical Evidence**: Previous studies with pimavanserin support the mechanism for remlifanserin [183][194] Regulatory and Market Challenges - **CHMP Negative Opinion**: Received a negative trend vote regarding Daybue, citing concerns over the clinical meaningfulness of endpoints [225][226] - **Reexamination Process**: Plans to apply for reexamination within the next few weeks, with a timeline of about **120 days** for review and decision [257][258] Other Pipeline Programs ACP-211 - **Differentiation from IV Ketamine**: ACP-211 is orally bioavailable and aims to provide a better patient experience with lower dissociation levels [275] - **Phase 2 Study Design**: Double-blind, randomized, placebo-controlled trial with a primary endpoint of MADRS scale at 4 weeks [288][289] Conclusion - ACADIA Pharmaceuticals is positioning itself for significant growth through its existing products and pipeline developments, while navigating regulatory challenges and expanding its market reach through innovative formulations and strategic marketing efforts.